IMPACT Medicom

IMPACT Medicom

By IMPACT MedicomScience
Download on the App Store

IMPACT Medicom episodes

  • Lung Cancer Screening: Western Canada

    Background

    • Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics) 
    • Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics) 
    • Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations. 
    • The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide. 
    • Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also. 
    • In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care. 

    Our Guests
    Dr. Stephen Lam: Professor of Medicine at the University of British Columbia and Medical Oncologist at BC Cancer. Dr. Lam is a Distinguished Scientist, and Leon Judah Blackmore Chair in Lung Cancer Research at the BC Cancer Research Center. He was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery and the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis, the Distinguished Achievement Award from the University of British Columbia and the Joseph Cullen Award for life-time scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer. 

    Dr. Rakesh Patel: General practitioner from Silverado Medical Clinic in Calgary, Alberta.

    Resources
    BC Press release http://www.bccancer.bc.ca/about/news-stories/news/2020/b-c-launches-lung-cancer-screening-program-%E2%80%93-the-first-in-canada

    CPAC Report: https://s22457.pcdn.co/wp-content/uploads/2021/01/lung-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdf

    TO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/

     If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    26 min
  • Dépistage du Cancer Du Poumon: Québec

    Renseignements généraux

    • Le cancer du poumon est l’une des formes de cancer les plus courantes ainsi que la principale cause de décès par cancer au Canada. (Statistiques canadiennes sur le cancer, 2020).
    • Le taux de survie des patients atteints d’un cancer du poumon est faible. La survie nette à trois ans est de 71 % pour les cas diagnostiqués au stade 1, et chute à 5 % pour les cas diagnostiqués au stade 4. Au Canada, environ la moitié des cancers du poumon ont atteint le stade 4 au moment du diagnostic. (Statistiques canadiennes sur le cancer, 2020).
    • Deux études cliniques, soit l’étude néerlando-belge sur le dépistage NELSON et une étude américaine nationale sur le dépistage du cancer du poumon (l’étude NLST), ont montré l’utilité du dépistage du cancer du poumon dans la réduction du taux de mortalité chez les populations à haut risque.
    • Au Canada, il y a consensus au sein de la communauté du cancer du poumon quant à la nécessité de mettre en œuvre des programmes de dépistage à l’échelle nationale.
    • On a annoncé la mise en œuvre de programmes de dépistage du cancer du poumon à l’échelle du Canada. L’Ontario et le Québec ont lancé les leurs en avril et en juin 2021, respectivement. La Colombie-Britannique a fait l’annonce de son programme en 2020; celui-ci sera lancé sous peu. D’autres provinces travaillent également à l’élaboration de programmes de dépistage. 
    • Dans cette série de balados, nous discuterons de l’importance du dépistage du cancer du poumon et des moyens de faire connaître ces programmes au Canada afin d’améliorer les soins offerts aux patients.

    Invités
    Dre Nicole Bouchard: Pneumologue au département de médecine de l’Université de Sherbrooke, Québec.

    Dr Richard Dumouchel:  Omnipraticien à la Clinique médicale du Coteau, à Saint-Jean-sur-Richelieu, Québec.

    Résources
    https://right2survive.ca/resource-centre/screening/
    https://www.quebec.ca/en/health/advice-and-prevention/screening-and-carrier-testing-offer/lung-cancer-screening-demonstration-project 

     If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.



    31 min
  • Lung Cancer Screening: National

    Background

    • Lung cancer is one of the most common cancers and is the leading cause of cancer death in Canada. (2020 Canadian Cancer Statistics) 
    • Survival from lung cancer is poor. Three-year net survival for lung cancer decreased from 71% among those diagnosed at stage 1 to 5% among those diagnosed at stage 4. Approximately half of all lung cancer cases in Canada are stage 4 at diagnosis. (2020 Canadian Cancer Statistics) 
    • Two clinical trials, the Dutch-Belgian screening trial (NELSON) and the United States National Lung Screening Trial (NLST), have demonstrated the value of lung cancer screening in reducing mortality rates in high-risk populations. 
    • The lung cancer community across Canada is therefore united in the belief that screening programs should be implemented nationwide. 
    • Lung Cancer Screening programs have been announced across Canada. The Ontario program launched in April 2021 and the program in Quebec launched in June 2021. A program in BC was announced in 2020 and will launch in the near future. Other provinces across Canada are working on developing screening programs also. 
    • In this podcast series, we discuss the importance of lung cancer screening and aim to raise awareness of these programs in Canada in order to improve patient care. 

    Our Guests
    Dr. Paul Wheatley-Price: Associate Professor in the Department of Medicine at the University of Ottawa and Medical Oncologist at The Ottawa Hospital Cancer Centre, specializing in the treatment of thoracic malignancies and carcinoma of unknown primary. Since 2016, Dr. Wheatley-Price has previously served as President of Lung Cancer Canada. 

    Dr. Jeffery Habert: General practitioner in Thornhill, ON and Assistant Professor in the Department of Family and Community Medicine at the University of Toronto.

    Resources
    ONTARIO

    • Lakeridge Health in Oshawa: https://www.lakeridgehealth.on.ca/en/central-east-regional-cancer-program/lung-cancer-screening-pilot.asp
    • The Ottawa Hospital: https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/what-we-offer-our-programs-and-services/lung-screening/
    • Health Sciences North in Sudbury: https://www.hsnsudbury.ca/portalen/rcp/hrlcsp
    • Princess Margaret Hospital in Toronto: https://www.trcp.ca/en/screening/screening-programs/Pages/lung.aspx

    BRITISH COLUMBIA

    • The BC Lung Screen Trial: http://www.bccancer.bc.ca/our-research/participate/lung-health

    CPAC Report: https://s22457.pcdn.co/wp-content/uploads/2021/01/lung-cancer-screening-environmental-scan-2019-2020-Jan132021-EN.pdf

    TO FIND A SCREENING PROGRAM NEAR YOU: https://right2survive.ca/resource-centre/screening/

     If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    26 min
  • Precision Medicine in Oncology: Ep.4 Access to Genomic Profiling in Quebec

    In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:

    ·       The initiatives developed by Colorectal Cancer Canada to help progress access to genomic profiling and precision medicine for all cancer patients 

    ·       The patient’s perspective on education, access, and value of genomic profiling

    ·       Access to genomic profiling in Quebec

    ·       The value of IMPACT Medicom’s comprehensive genomic profiling prioritization report: https://www.impactmedicom.com/publications/reports

    Our guest:

    Barry D. Stein is the President and CEO of Colorectal Cancer Canada and is himself a survivor of metastatic colorectal cancer. He is an established lawyer in the fields of commercial and corporate law with GWBR, LLP in Montreal, where he dedicates a significant portion of his practice to labour law, as well as litigation in health and administrative law. Barry is the past president of the Coalition Priorité Cancer au Québec. He is also past chair of the IQVIA Advisory Council for the Advancement of Health in Quebec and a member of the Board of Directors of the Canadian Personalized Healthcare Innovation Network, EXACTIS Innovation, and the Quebec Clinical Research Organization in Cancer (Q-CROC).
     
     If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    34 min
  • Treatment of Relapsed/Refractory Hodgkin's Lymphoma

    In this episode of our podcast, we are joined by a very special guest, Dr. John Kuruvilla, who is an Associate Professor of Medicine at the University of Toronto and a Clinical Investigator in the Division of Medical Oncology and Hematology at Princess Margaret Hospital in Toronto. 

    We discuss:

    • The current treatment of classical Hodgkin’s Lymphoma 
    • The use of checkpoint inhibitors for these patients 
    • Results of the KEYNOTE-204 trial, a randomized phase III trial of pembrolizumab versus brentuximab vedotin in relapsed or refractory Hodgkin’s Lymphoma
    • How future research will address some key questions in this area


    This podcast episode is sponsored by Merck Canada.  


    If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    31 min
  • MYTHBUSTERS: Addressing COVID-19 Vaccine Hesitancy Ep 3

    Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines. 

    In the third episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom),  we discuss with Dr. Raywat Deonandan:

    • Strategies and tactics for discussing myths around COVID-19 with the public
    • The difference between individual and population risk and how to discuss these concepts 
    • Lessons we can learn from other countries and experiences
    • The efficacy of COVID-19 vaccines against known variants


    Our guest
    Dr. Ray Deonandan is an Epidemiologist and Associate Professor at the University of Ottawa, specializing in global health. Dr. Deonandan is a well-known science communicator, appearing on numerous news outlets throughout the COVID-19 pandemic in his effort to educate the public on the latest data. 

    This podcast episode is sponsored by AstraZeneca Canada.  


    If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    34 min
  • Precision Medicine in Oncology: Ep.3 Access to Genomic Profiling in Ontario

    Podcast details:

    In this episode of IMPACT Medicom’s podcast series on Precision Medicine in Oncology we discuss:

    ·       The evolving role of genomics in a pathologist’s tool kit for informing care in oncology

    ·       The value of comprehensive genomic profiling (CGP) compared to single-gene tests

    ·       The barriers to accessing CGP in Ontario

    ·       What factors institutions should consider when deciding how to implement CGP 

    Our guest:

    Dr. Brandon Sheffield is an anatomical pathologist at William Osler Health System in Brampton, Ontario, where he serves as Medical Director of Immunohistochemistry and Molecular Pathology, and Physician Lead of Research. He received his Doctor of Medicine at the University of Toronto and completed his anatomical pathology residency at the University of British Columbia. Given his interest in molecular genetic pathology, Dr. Sheffield played an integral role in acquiring William Osler’s new rapid comprehensive next generation sequencing technology, making Osler the first community hospital in the world to offer this type of genetic testing in-house for their cancer patients. 

    Brandon also served as a steering committee member on IMPACT Medicom’s CGP prioritization report. The full report can be downloaded at: https://www.impactmedicom.com/publications/reports 

     

    This podcast episode was sponsored by AstraZeneca Canada.

     

    If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com 

    35 min
  • MYTHBUSTERS: Addressing COVID-19 Vaccine Hesitancy Ep 2

    Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines. 

    In the second episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom),  we discuss with Dr. Lynora Saxinger:

    • Common concerns that may lead to COVID-19 vaccine hesitancy 
    • The scientific evidence behind these concerns and how they can be addressed with patients
    • The latest safety data, in particular, the risk of blood clots 
    • Data around length of immunity and optimal dosing schedules


    Our guest
    Dr. Lynora Saxinger is a world-renowned infectious disease specialist, based at the University of Alberta. Dr. Saxinger has been at the forefront of the media, becoming a National public figure in the discussions around COVID-19.

    This podcast episode is sponsored by AstraZeneca Canada.  


    If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    37 min
  • MYTHBUSTERS: Addressing COVID-19 Vaccine Hesitancy Ep1 Part2

    Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines. 

    In the second part of the first episode of the series,  hosted by Anna Christofides (owner of IMPACT Medicom), we  continue the discussion on:

    • Addressing Vaccine Hesitancy: Common sources of misinformation around COVID-19 vaccination and how these can be addressed
    • Improving Vaccine Access: The use of mass vaccination and popup clinics to provide better access to higher risk populations


    Our guest
    Dr. Kelly Grindrod is an associate professor at the University of Waterloo’s School of Pharmacy. She is the pharmacy lead for the Waterloo Region vaccine task force and helped set up a mass vaccine clinic at the University of Waterloo School of Pharmacy. Dr. Grindrod has also led the development of several online resources including the Pharmacy5in5.ca platform, which includes videos and infographics on COVID vaccines.

    This podcast episode is sponsored by AstraZeneca Canada.  


    If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    Episode is Live

    Published: Apr. 14, 2021 @ 2PM Edit

    Unpublish

    Add a Transcript

    Get episode better indexed by search engines.

    Add Chapter Markers

    Listeners can tap through & see what’s coming up.

    Create a Visual Soundbite
    Best way to share to social media for engagement.

    Share Episode On

    Facebook

    Twitter

    LinkedIn

    More Options

    Email Link to Episode
    Copy

    Direct Link to MP3
    Copy Download MP3

    Embed this ONE Episode



    39 min
  • MYTHBUSTERS: Addressing COVID-19 Vaccine Hesitancy Ep1 Part 1

    Welcome to IMPACT Medicom’s MYTHBUSTER series, addressing COVID-19 vaccine hesitancy. This series is aimed at health care professionals who are on the front lines of vaccine delivery, to help address common sources of misinformation around COVID-19 vaccines. 

    In our first episode of the series, hosted by Anna Christofides (owner of IMPACT Medicom), we discuss with Dr. Kelly Grindrod:

    • Addressing Vaccine Hesitancy: Common sources of misinformation around COVID-19 vaccination and how these can be addressed
    • Improving Vaccine Access: The use of mass vaccination and popup clinics to provide better access to higher risk populations


    Our guest
    Dr. Kelly Grindrod is an associate professor at the University of Waterloo’s School of Pharmacy. She is the pharmacy lead for the Waterloo Region vaccine task force and helped set up a mass vaccine clinic at the University of Waterloo School of Pharmacy. Dr. Grindrod has also led the development of several online resources including the Pharmacy5in5.ca platform, which includes videos and infographics on COVID vaccines.

    This podcast episode is sponsored by AstraZeneca Canada.  


    If you enjoy our podcast, please review and subscribe. For more podcasts, papers, and medical education programs, visit our website at: http://www.impactmedicom.com.

    29 min

About IMPACT Medicom

From the publisher's feed

We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic…

More shows like IMPACT Medicom

The Daily by The New York Times

The Daily

112,262 Listeners